BR9611311A - Derivados de 5-fenil-3-(piperidin-4-il)-1,3,4-oxadiazol-2(3h)-ona úteis como ligantes dos receptores 5-ht4 ou h3 - Google Patents
Derivados de 5-fenil-3-(piperidin-4-il)-1,3,4-oxadiazol-2(3h)-ona úteis como ligantes dos receptores 5-ht4 ou h3Info
- Publication number
- BR9611311A BR9611311A BR9611311A BR9611311A BR9611311A BR 9611311 A BR9611311 A BR 9611311A BR 9611311 A BR9611311 A BR 9611311A BR 9611311 A BR9611311 A BR 9611311A BR 9611311 A BR9611311 A BR 9611311A
- Authority
- BR
- Brazil
- Prior art keywords
- oxadiazole
- piperidin
- phenyl
- receptor ligands
- derivatives useful
- Prior art date
Links
- RJIHZTHWMPTLQL-UHFFFAOYSA-N 5-phenyl-3-piperidin-4-yl-1,3,4-oxadiazol-2-one Chemical class O=C1OC(C=2C=CC=CC=2)=NN1C1CCNCC1 RJIHZTHWMPTLQL-UHFFFAOYSA-N 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9513253A FR2741070B1 (fr) | 1995-11-09 | 1995-11-09 | Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique |
| FR9513252A FR2741069B1 (fr) | 1995-11-09 | 1995-11-09 | Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique |
| FR9602663A FR2745574B1 (fr) | 1996-03-04 | 1996-03-04 | Derives de 5-phenyl-3-(piperidin-4-yl)-1, 3, 4-oxadiazol-2 (3h)-one, leur preparation et leur application en therapeutique |
| PCT/FR1996/001730 WO1997017345A1 (fr) | 1995-11-09 | 1996-11-05 | Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h)-one, utiles comme ligands des recepteurs 5-ht4 ou h¿3? |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9611311A true BR9611311A (pt) | 1999-06-29 |
Family
ID=27253120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9611311A BR9611311A (pt) | 1995-11-09 | 1996-11-05 | Derivados de 5-fenil-3-(piperidin-4-il)-1,3,4-oxadiazol-2(3h)-ona úteis como ligantes dos receptores 5-ht4 ou h3 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US5929089A (enExample) |
| EP (1) | EP0863897B1 (enExample) |
| JP (1) | JP4263240B2 (enExample) |
| CN (1) | CN1077891C (enExample) |
| AR (1) | AR004708A1 (enExample) |
| AT (1) | ATE181328T1 (enExample) |
| AU (1) | AU707325B2 (enExample) |
| BG (1) | BG63463B1 (enExample) |
| BR (1) | BR9611311A (enExample) |
| CA (1) | CA2236357C (enExample) |
| CO (1) | CO4770968A1 (enExample) |
| CZ (1) | CZ287268B6 (enExample) |
| DE (1) | DE69602970T2 (enExample) |
| EE (1) | EE03487B1 (enExample) |
| ES (1) | ES2135934T3 (enExample) |
| GR (1) | GR3030823T3 (enExample) |
| HU (1) | HUP0001168A3 (enExample) |
| IL (1) | IL124364A (enExample) |
| MX (1) | MX9803696A (enExample) |
| NO (1) | NO309606B1 (enExample) |
| NZ (1) | NZ321626A (enExample) |
| PL (1) | PL186204B1 (enExample) |
| RU (1) | RU2167160C2 (enExample) |
| SI (1) | SI0863897T1 (enExample) |
| SK (1) | SK282335B6 (enExample) |
| TR (1) | TR199800827T2 (enExample) |
| TW (1) | TW371303B (enExample) |
| UA (1) | UA50748C2 (enExample) |
| WO (1) | WO1997017345A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW467902B (en) * | 1996-07-31 | 2001-12-11 | Bristol Myers Squibb Co | Diphenyl heterocycles as potassium channel modulators |
| FR2762316B1 (fr) * | 1997-04-18 | 1999-12-17 | Sanofi Synthelabo | Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique |
| FR2763068B1 (fr) * | 1997-05-06 | 1999-06-04 | Synthelabo | Derives de 3-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique |
| AU7658798A (en) * | 1997-05-06 | 1998-11-27 | Synthelabo | 5-phenyl-1,3,4-oxadiazol-2(3h)-one derivatives and their use as 5-ht4 ligands |
| GB9715816D0 (en) * | 1997-07-25 | 1997-10-01 | Black James Foundation | Histamine H receptor ligands |
| US6960579B1 (en) | 1998-05-19 | 2005-11-01 | Alcon Manufacturing, Ltd. | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders |
| ES2252978T3 (es) | 1998-09-18 | 2006-05-16 | Alcon Manufacturing Ltd. | Agonistas 5ht2 serotonergicos para tratar el glaucoma. |
| CN1461216A (zh) * | 1999-04-28 | 2003-12-10 | 呼吸器有限公司 | 用作治疗有关支气管收缩的机能障碍的药物的化合物 |
| JP2003501462A (ja) * | 1999-06-15 | 2003-01-14 | レスピラトリウス アクチボラゲット | 受容体アゴニストおよびアンタゴニスト |
| CZ2003686A3 (cs) * | 2000-08-08 | 2003-08-13 | Ortho Mcneil Pharmaceutical, Inc. | Neimidazolové aryloxypiperidiny |
| MXPA03001267A (es) | 2000-08-08 | 2004-07-30 | Johnson & Johnson | Ariloxialquilaminas sin imidazol. |
| PT1311499E (pt) | 2000-08-08 | 2006-07-31 | Ortho Mcneil Pharm Inc | Compostos biciclicos como ligandos do receptor h3 |
| US7208497B2 (en) | 2001-07-02 | 2007-04-24 | Novo Nordisk A/S | Substituted piperazines and diazepanes |
| ATE449090T1 (de) | 2001-07-02 | 2009-12-15 | High Point Pharmaceuticals Llc | Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren |
| US6673829B2 (en) | 2001-09-14 | 2004-01-06 | Novo Nordisk A/S | Aminoazetidine,-pyrrolidine and -piperidine derivatives |
| EP1434765B1 (en) * | 2001-09-14 | 2009-12-02 | High Point Pharmaceuticals, LLC | Substituted piperidines with selective binding to histamine h3-receptor |
| JP4619655B2 (ja) | 2001-09-14 | 2011-01-26 | ハイ・ポイント・ファーマスーティカルズ、エルエルシー | 新規アミノアゼチジン、−ピロリジンおよび−ピペリジン誘導体 |
| US20030186963A1 (en) | 2001-09-14 | 2003-10-02 | Dorwald Florencio Zaragoza | Substituted piperidines |
| US7064135B2 (en) | 2001-10-12 | 2006-06-20 | Novo Nordisk Inc. | Substituted piperidines |
| WO2003031432A1 (en) | 2001-10-12 | 2003-04-17 | Novo Nordisk A/S | Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor |
| US7005448B2 (en) | 2001-12-14 | 2006-02-28 | Alcon, Inc. | Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma |
| US20030236259A1 (en) * | 2002-02-05 | 2003-12-25 | Rolf Hohlweg | Novel aryl- and heteroarylpiperazines |
| GB0211230D0 (en) | 2002-05-16 | 2002-06-26 | Medinnova Sf | Treatment of heart failure |
| US7332508B2 (en) * | 2002-12-18 | 2008-02-19 | Novo Nordisk A/S | Substituted homopiperidine, piperidine or pyrrolidine derivatives |
| GB0325956D0 (en) * | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| EA010891B9 (ru) | 2004-06-15 | 2012-08-30 | Пфайзер Инк. | Производные бензимидазолонкарбоновой кислоты |
| US7737163B2 (en) | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
| EP2386554A1 (en) * | 2005-07-04 | 2011-11-16 | High Point Pharmaceuticals, LLC | Compounds active at the histamine H3 receptor |
| RU2396269C2 (ru) * | 2005-12-01 | 2010-08-10 | Ф.Хоффманн-Ля Рош Аг | Производные гетероарилзамещенного пиперидина в качестве ингибиторов печеночной карнитин пальмитоилтрансферазы (l-cpt1) |
| MX2008014766A (es) * | 2006-05-29 | 2009-03-06 | High Point Pharmaceuticals Llc | 3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperazin-1-il)-piperazi na, sus sales y solvatos y su uso como antagonista del receptor de h3 histamina. |
| EP2014656A3 (en) * | 2007-06-11 | 2011-08-24 | High Point Pharmaceuticals, LLC | New heteocyclic h3 antagonists |
| ME02107B (me) | 2011-09-19 | 2015-10-20 | Heteroaril jedinjenja kao ligandi 5-ht4 receptora |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5055476A (en) * | 1990-08-13 | 1991-10-08 | Hoechst-Roussel Pharmaceuticals Incorporated | 3-(1,2-benzisoxazol-3-yl)-4-pyridinamines and derivatives |
| AU2435092A (en) * | 1991-08-20 | 1993-03-16 | Smithkline Beecham Plc | 5-ht4 receptor antagonists |
| CA2118812C (en) * | 1991-09-12 | 2006-01-17 | Francis David King | 5-ht4 receptor antagonists |
| CA2129112A1 (en) * | 1992-02-06 | 1993-08-19 | Francis David King | Benzopyran, benzothiopyran and benzofuran derivatives as 5-ht4 antagonists |
| GB9219163D0 (en) * | 1992-09-10 | 1992-10-28 | Smithkline Beecham Plc | Pharmaceuticals |
| JPH06157518A (ja) * | 1992-11-27 | 1994-06-03 | Yamanouchi Pharmaceut Co Ltd | 新規なオキサジアゾール誘導体又はその塩 |
-
1996
- 1996-11-05 AT AT96937390T patent/ATE181328T1/de active
- 1996-11-05 DE DE69602970T patent/DE69602970T2/de not_active Expired - Lifetime
- 1996-11-05 CN CN96198208A patent/CN1077891C/zh not_active Expired - Fee Related
- 1996-11-05 SK SK599-98A patent/SK282335B6/sk not_active IP Right Cessation
- 1996-11-05 CA CA002236357A patent/CA2236357C/en not_active Expired - Fee Related
- 1996-11-05 BR BR9611311A patent/BR9611311A/pt not_active IP Right Cessation
- 1996-11-05 WO PCT/FR1996/001730 patent/WO1997017345A1/fr not_active Ceased
- 1996-11-05 RU RU98110976/04A patent/RU2167160C2/ru not_active IP Right Cessation
- 1996-11-05 NZ NZ321626A patent/NZ321626A/xx not_active IP Right Cessation
- 1996-11-05 UA UA98031589A patent/UA50748C2/uk unknown
- 1996-11-05 SI SI9630092T patent/SI0863897T1/xx not_active IP Right Cessation
- 1996-11-05 JP JP51791797A patent/JP4263240B2/ja not_active Expired - Fee Related
- 1996-11-05 US US09/068,390 patent/US5929089A/en not_active Expired - Lifetime
- 1996-11-05 CZ CZ19981421A patent/CZ287268B6/cs not_active IP Right Cessation
- 1996-11-05 TR TR1998/00827T patent/TR199800827T2/xx unknown
- 1996-11-05 HU HU0001168A patent/HUP0001168A3/hu unknown
- 1996-11-05 EE EE9800155A patent/EE03487B1/xx not_active IP Right Cessation
- 1996-11-05 ES ES96937390T patent/ES2135934T3/es not_active Expired - Lifetime
- 1996-11-05 PL PL96326671A patent/PL186204B1/pl not_active IP Right Cessation
- 1996-11-05 AU AU75001/96A patent/AU707325B2/en not_active Ceased
- 1996-11-05 IL IL12436496A patent/IL124364A/xx not_active IP Right Cessation
- 1996-11-05 EP EP96937390A patent/EP0863897B1/fr not_active Expired - Lifetime
- 1996-11-07 TW TW085113594A patent/TW371303B/zh not_active IP Right Cessation
- 1996-11-08 CO CO96059097A patent/CO4770968A1/es unknown
- 1996-11-08 AR ARP960105098A patent/AR004708A1/es active IP Right Grant
-
1998
- 1998-04-28 BG BG102412A patent/BG63463B1/bg unknown
- 1998-05-07 NO NO982092A patent/NO309606B1/no not_active IP Right Cessation
- 1998-05-08 MX MX9803696A patent/MX9803696A/es unknown
-
1999
- 1999-07-20 GR GR990401913T patent/GR3030823T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9611311A (pt) | Derivados de 5-fenil-3-(piperidin-4-il)-1,3,4-oxadiazol-2(3h)-ona úteis como ligantes dos receptores 5-ht4 ou h3 | |
| DE69325167D1 (de) | Kondensierte indol-derivate als 5-ht4-rezeptor-antagonisten | |
| PT871619E (pt) | Derivados de fenil-tiazol com propriedades anti-virus do herpesc | |
| DE69732105D1 (de) | Programmerweiterbare, implantierbare, medizinische vorrichtung | |
| IL133960A0 (en) | 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives | |
| DE69801905D1 (de) | 5-aryl-3-(8-azabicyclo[3.2.1]oct-3-yl)-1,3,4-oxadiazol-2(3h)-one derivate als 5-ht4 rezeptor liganden | |
| FI890520L (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 2- (piperidin-4-ylmetyl) -1,2,3,4 -tetrahydroisokinolinderivat. | |
| DE58907381D1 (de) | Ungesättigte Derivate von 2,2,6,6-Tetramethylpiperidin. | |
| DE69600278D1 (de) | Tretkurbellager-Anordnung | |
| DK0863897T3 (da) | Derivater af 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-on, som kan anvendes som ligander for 5-HT4- eller H3-recept | |
| FR2741070B1 (fr) | Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique | |
| FR2741069B1 (fr) | Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique | |
| FR2745574B1 (fr) | Derives de 5-phenyl-3-(piperidin-4-yl)-1, 3, 4-oxadiazol-2 (3h)-one, leur preparation et leur application en therapeutique | |
| PT90086A (pt) | Unidade de assento ou recostamento regulavel | |
| BR9510036A (pt) | Derivados de 1,3,4-oxadiazina | |
| FR2759699B1 (fr) | Derives de 5-(2,3-dihydro-1,4-benzoxazin-5-yl)-3-(piperidin- 4-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique | |
| BR9704191A (pt) | Colheitadeira-moageira de cana-de-açucar | |
| FR2763068B1 (fr) | Derives de 3-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique | |
| BR9105112A (pt) | Aperfeicoamentos em reservatorio de sanque,derivados ou substitutos | |
| FR2763069B1 (fr) | Derives de 1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique | |
| DK1133494T3 (da) | 8-Azabicyclo[3.2.1]oct-2-en-derivater | |
| BR9104505A (pt) | Maquina seletora de graos ou semelhantes | |
| ES1013661Y (es) | Fresadora de testa perfeccionada. | |
| BR9603253A (pt) | Derivados de camptotecina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Transfer |
Free format text: SANOFI-SYNTHELABO (FR) |
|
| FB36 | Technical and formal requirements: requirement - article 36 of industrial property law | ||
| HJEG | Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law | ||
| FF | Decision: intention to grant | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: SANOFI-AVENTIS (FR) Free format text: ALTERADO DE: SANOFI-SYNTHELABO |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2278 DE 02-09-2014 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |